Cantel Medical Corp. (NYSE:CMD) Chairman Charles M. Diker sold 20,500 shares of the business’s stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $99.15, for a total transaction of $2,032,575.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of Cantel Medical Corp. (CMD) opened at 97.07 on Friday. The stock’s 50 day moving average is $84.24 and its 200 day moving average is $77.67. The firm has a market cap of $4.03 billion, a PE ratio of 56.77 and a beta of 1.25. Cantel Medical Corp. has a 12 month low of $68.19 and a 12 month high of $99.83.

Cantel Medical Corp. (NYSE:CMD) last posted its earnings results on Thursday, September 28th. The company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.52 by $0.02. The firm had revenue of $205.50 million during the quarter, compared to analysts’ expectations of $200.32 million. Cantel Medical Corp. had a net margin of 9.27% and a return on equity of 17.60%. The business’s revenue for the quarter was up 14.8% compared to the same quarter last year. Analysts forecast that Cantel Medical Corp. will post $2.34 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Charles M. Diker Sells 20,500 Shares of Cantel Medical Corp. (CMD) Stock” was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/charles-m-diker-sells-20500-shares-of-cantel-medical-corp-cmd-stock/1611702.html.

A number of equities analysts have weighed in on the stock. Benchmark Co. downgraded shares of Cantel Medical Corp. from a “buy” rating to a “hold” rating in a research note on Friday, June 9th. Needham & Company LLC reaffirmed a “hold” rating on shares of Cantel Medical Corp. in a research note on Friday, September 1st. Zacks Investment Research downgraded shares of Cantel Medical Corp. from a “buy” rating to a “sell” rating in a research note on Wednesday, August 2nd. Finally, Sidoti raised shares of Cantel Medical Corp. from a “neutral” rating to a “buy” rating and set a $92.00 target price for the company in a research note on Wednesday, August 2nd. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $91.67.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Globeflex Capital L P bought a new position in Cantel Medical Corp. in the 2nd quarter valued at approximately $114,000. Integrated Investment Consultants LLC bought a new position in Cantel Medical Corp. in the 2nd quarter valued at approximately $161,000. LS Investment Advisors LLC bought a new position in Cantel Medical Corp. in the 2nd quarter valued at approximately $172,000. Airain ltd bought a new position in Cantel Medical Corp. in the 2nd quarter valued at approximately $201,000. Finally, Punch & Associates Investment Management Inc. bought a new position in Cantel Medical Corp. in the 2nd quarter valued at approximately $212,000. Institutional investors and hedge funds own 83.79% of the company’s stock.

Cantel Medical Corp. Company Profile

Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.

Insider Buying and Selling by Quarter for Cantel Medical Corp. (NYSE:CMD)

Receive News & Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.